{"id":"W4391303561","doi":"10.1200/jco.2024.42.4_suppl.2","title":"First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Lenvatinib; Pembrolizumab; Medicine; Renal cell carcinoma; Internal medicine; Oncology; Clear cell; Phases of clinical research; Cancer research; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003730673,0.0008045668,0.001206054,0.000303688,0.0005710892,0.0009463347,0.0006403386,0.0007124409,0.003479611],"category_scores_gemma":[0.001198114,0.0004274399,0.001047942,0.0003919142,0.0003389197,0.0009116607,0.0005583644,0.001813514,0.0008089561],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008190665,"about_ca_system_score_gemma":0.001285423,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007958413,"about_ca_topic_score_gemma":0.002069234,"domain_scores_codex":[0.9993044,0.0002831061,0.00004652642,0.0001228995,0.0001332584,0.0001096646],"domain_scores_gemma":[0.9992263,0.00009111464,0.0002048631,0.0001101029,0.00007760451,0.0002899854],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6465653,0.03077889,0.1128028,0.002404015,0.006953104,0.0007795548,0.000458189,0.002734762,0.02292399,0.0004708235,0.01608121,0.1570475],"study_design_scores_gemma":[0.3649042,0.2736681,0.3142329,0.0003153993,0.005467013,0.002028415,0.0001800245,0.001796867,0.00635528,0.0004427542,0.0305312,0.00007789404],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9747061,0.005974158,0.0008933991,0.000344077,0.0001198831,0.005888019,0.006967826,0.00009418673,0.00501237],"genre_scores_gemma":[0.9709218,0.001856854,0.001679748,0.0008316863,0.0001449851,0.003311981,0.01780105,0.00003024141,0.003421634],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003730673,"threshold_uncertainty_score":0.01972991,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1359062445362326,"score_gpt":0.4478767421619031,"score_spread":0.3119704976256705,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}